Evaluation of melatonin treatment in primary culture of canine mammary tumors
Mammary neoplasias are the most common tumors observed in female dogs. Identification of these tumors is valuable in order to identify beneficial therapeutic agents as alternative treatments for this tumor type. Oral administration of melatonin appears to exert an oncostatic effect on mammary neopla...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2015-01, Vol.33 (1), p.311-319 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 1 |
| container_start_page | 311 |
| container_title | Oncology reports |
| container_volume | 33 |
| creator | LOPES, JULIANA RAMOS MASCHIO, LARISSA BAZELA JARDIM-PERASSI, BRUNA VICTORASSO MOSCHETTA, MARINA GOBBE FERREIRA, LÍVIA CARVALHO MARTINS, GUSTAVO RODRIGUES GELALETI, GABRIELA BOTTARO DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES |
| description | Mammary neoplasias are the most common tumors observed in female dogs. Identification of these tumors is valuable in order to identify beneficial therapeutic agents as alternative treatments for this tumor type. Oral administration of melatonin appears to exert an oncostatic effect on mammary neoplasia and may have a possible mechanism of action through its interaction with estrogen receptors on epithelial cells. Hence, we analyzed the potential therapeutic value of melatonin in tumors that are estrogen-dependent or -independent, and established a relationship of its action with the expression of the melatonin receptors MT1 and MT2. Furthermore, we analyzed the rate of cell proliferation and apoptosis after treatment with melatonin. Cell cultures were performed using 10 canine mammary tumor fragments and were divided into estrogen receptor (ER)-positive and ER-negative tumors. The results showed that both ER-positive and ER-negative tumors had decreased cell viability and proliferation after treatment with melatonin (p |
| doi_str_mv | 10.3892/or.2014.3596 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1628241856</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A401380414</galeid><sourcerecordid>A401380414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-a7902f2a1987a425c8bb4336a01d02506ebb2709a301775d60adf06b1d8a60ad3</originalsourceid><addsrcrecordid>eNptks9v1TAMxysEYmNw44wqISEO9GEnaZocp2n8kIa4gMQtctuUdUqTR5JO4r8nZY-NIZRDnPhjx_Y3VfUcYceVZm9D3DFAseOtlg-qY-w0NkxwfFhsYNhw3n47qp6kdAXAOpD6cXXEWq5EK_Vx9en8mtxKeQ6-DlO9WEc5-NnXOVrKi_W5Lod9nBeKP-thdXmNdiMHKpStF1p-e_K6hJieVo8mcsk-O-wn1dd351_OPjQXn99_PDu9aAahZG6o08AmRqhVR4K1g-p7wbkkwBFYC9L2fSlVEwfsunaUQOMEssdR0Wbzk-r1Td59DD9Wm7JZ5jRY58jbsCaDkikmULWyoC__Qa_CGn2pzqDmTLYKNL-jvpOzZvZTyJGGLak5FYBcgUBRqN1_qLJGu8xD8Haay_29gFd_BVxacvkyBbdu4073wTc34BBDStFO5jByg2A2mU2IZpPZbDIX_MWhqbVf7HgL_9H17uG0Jz_OY0i3TIjlSzSADXBE_gu8nqvX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932658093</pqid></control><display><type>article</type><title>Evaluation of melatonin treatment in primary culture of canine mammary tumors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>LOPES, JULIANA RAMOS ; MASCHIO, LARISSA BAZELA ; JARDIM-PERASSI, BRUNA VICTORASSO ; MOSCHETTA, MARINA GOBBE ; FERREIRA, LÍVIA CARVALHO ; MARTINS, GUSTAVO RODRIGUES ; GELALETI, GABRIELA BOTTARO ; DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</creator><creatorcontrib>LOPES, JULIANA RAMOS ; MASCHIO, LARISSA BAZELA ; JARDIM-PERASSI, BRUNA VICTORASSO ; MOSCHETTA, MARINA GOBBE ; FERREIRA, LÍVIA CARVALHO ; MARTINS, GUSTAVO RODRIGUES ; GELALETI, GABRIELA BOTTARO ; DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</creatorcontrib><description>Mammary neoplasias are the most common tumors observed in female dogs. Identification of these tumors is valuable in order to identify beneficial therapeutic agents as alternative treatments for this tumor type. Oral administration of melatonin appears to exert an oncostatic effect on mammary neoplasia and may have a possible mechanism of action through its interaction with estrogen receptors on epithelial cells. Hence, we analyzed the potential therapeutic value of melatonin in tumors that are estrogen-dependent or -independent, and established a relationship of its action with the expression of the melatonin receptors MT1 and MT2. Furthermore, we analyzed the rate of cell proliferation and apoptosis after treatment with melatonin. Cell cultures were performed using 10 canine mammary tumor fragments and were divided into estrogen receptor (ER)-positive and ER-negative tumors. The results showed that both ER-positive and ER-negative tumors had decreased cell viability and proliferation after treatment with melatonin (p<0.05), although treatment was more effective in the ER-positive tumors. Analysis of the relative expression of the MT1 and MT2 genes by quantitative PCR was performed and the data were compared with the expression of ER in 24 canine mammary tumors and the cellular response to melatonin in 10 samples. MT1 was overexpressed in ER-positive tumors (p<0.05), whereas MT2 was not expressed. Furthermore, melatonin treatment in ER-positive tumors showed an efficient oncostatic effect by inhibiting cell viability and proliferation and inducing apoptosis. These results suggest that melatonin decreased neoplastic mammary cell proliferation and viability and induced apoptosis, with greater efficacy in ER-positive tumors that have a high expression of melatonin receptor MT1. This is a strong evidence for the use of melatonin as a therapeutic agent for estrogen-dependent canine mammary tumors.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2014.3596</identifier><identifier>PMID: 25384569</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Analysis ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis ; Breast cancer ; Cell growth ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Dog Diseases - drug therapy ; Dog Diseases - metabolism ; Dogs ; Drug Screening Assays, Antitumor ; Drug therapy ; Estrogen ; estrogen receptor ; Estrogens ; Female ; Gene Expression ; Genetic aspects ; Health aspects ; immunocytochemistry ; Lymphatic system ; Mammary Neoplasms, Animal - drug therapy ; Mammary Neoplasms, Animal - metabolism ; Medical prognosis ; Melatonin ; Melatonin - pharmacology ; Metastasis ; MT1 ; MT2 ; Physiological aspects ; Primary Cell Culture ; Receptor, Melatonin, MT1 - genetics ; Receptor, Melatonin, MT1 - metabolism ; Receptor, Melatonin, MT2 - genetics ; Receptor, Melatonin, MT2 - metabolism ; Rodents ; Tumor Cells, Cultured ; Tumors</subject><ispartof>Oncology reports, 2015-01, Vol.33 (1), p.311-319</ispartof><rights>Copyright © 2015, Spandidos Publications</rights><rights>COPYRIGHT 2015 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-a7902f2a1987a425c8bb4336a01d02506ebb2709a301775d60adf06b1d8a60ad3</citedby><cites>FETCH-LOGICAL-c486t-a7902f2a1987a425c8bb4336a01d02506ebb2709a301775d60adf06b1d8a60ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25384569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LOPES, JULIANA RAMOS</creatorcontrib><creatorcontrib>MASCHIO, LARISSA BAZELA</creatorcontrib><creatorcontrib>JARDIM-PERASSI, BRUNA VICTORASSO</creatorcontrib><creatorcontrib>MOSCHETTA, MARINA GOBBE</creatorcontrib><creatorcontrib>FERREIRA, LÍVIA CARVALHO</creatorcontrib><creatorcontrib>MARTINS, GUSTAVO RODRIGUES</creatorcontrib><creatorcontrib>GELALETI, GABRIELA BOTTARO</creatorcontrib><creatorcontrib>DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</creatorcontrib><title>Evaluation of melatonin treatment in primary culture of canine mammary tumors</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>Mammary neoplasias are the most common tumors observed in female dogs. Identification of these tumors is valuable in order to identify beneficial therapeutic agents as alternative treatments for this tumor type. Oral administration of melatonin appears to exert an oncostatic effect on mammary neoplasia and may have a possible mechanism of action through its interaction with estrogen receptors on epithelial cells. Hence, we analyzed the potential therapeutic value of melatonin in tumors that are estrogen-dependent or -independent, and established a relationship of its action with the expression of the melatonin receptors MT1 and MT2. Furthermore, we analyzed the rate of cell proliferation and apoptosis after treatment with melatonin. Cell cultures were performed using 10 canine mammary tumor fragments and were divided into estrogen receptor (ER)-positive and ER-negative tumors. The results showed that both ER-positive and ER-negative tumors had decreased cell viability and proliferation after treatment with melatonin (p<0.05), although treatment was more effective in the ER-positive tumors. Analysis of the relative expression of the MT1 and MT2 genes by quantitative PCR was performed and the data were compared with the expression of ER in 24 canine mammary tumors and the cellular response to melatonin in 10 samples. MT1 was overexpressed in ER-positive tumors (p<0.05), whereas MT2 was not expressed. Furthermore, melatonin treatment in ER-positive tumors showed an efficient oncostatic effect by inhibiting cell viability and proliferation and inducing apoptosis. These results suggest that melatonin decreased neoplastic mammary cell proliferation and viability and induced apoptosis, with greater efficacy in ER-positive tumors that have a high expression of melatonin receptor MT1. This is a strong evidence for the use of melatonin as a therapeutic agent for estrogen-dependent canine mammary tumors.</description><subject>Analysis</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Breast cancer</subject><subject>Cell growth</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Dog Diseases - drug therapy</subject><subject>Dog Diseases - metabolism</subject><subject>Dogs</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Drug therapy</subject><subject>Estrogen</subject><subject>estrogen receptor</subject><subject>Estrogens</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>immunocytochemistry</subject><subject>Lymphatic system</subject><subject>Mammary Neoplasms, Animal - drug therapy</subject><subject>Mammary Neoplasms, Animal - metabolism</subject><subject>Medical prognosis</subject><subject>Melatonin</subject><subject>Melatonin - pharmacology</subject><subject>Metastasis</subject><subject>MT1</subject><subject>MT2</subject><subject>Physiological aspects</subject><subject>Primary Cell Culture</subject><subject>Receptor, Melatonin, MT1 - genetics</subject><subject>Receptor, Melatonin, MT1 - metabolism</subject><subject>Receptor, Melatonin, MT2 - genetics</subject><subject>Receptor, Melatonin, MT2 - metabolism</subject><subject>Rodents</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptks9v1TAMxysEYmNw44wqISEO9GEnaZocp2n8kIa4gMQtctuUdUqTR5JO4r8nZY-NIZRDnPhjx_Y3VfUcYceVZm9D3DFAseOtlg-qY-w0NkxwfFhsYNhw3n47qp6kdAXAOpD6cXXEWq5EK_Vx9en8mtxKeQ6-DlO9WEc5-NnXOVrKi_W5Lod9nBeKP-thdXmNdiMHKpStF1p-e_K6hJieVo8mcsk-O-wn1dd351_OPjQXn99_PDu9aAahZG6o08AmRqhVR4K1g-p7wbkkwBFYC9L2fSlVEwfsunaUQOMEssdR0Wbzk-r1Td59DD9Wm7JZ5jRY58jbsCaDkikmULWyoC__Qa_CGn2pzqDmTLYKNL-jvpOzZvZTyJGGLak5FYBcgUBRqN1_qLJGu8xD8Haay_29gFd_BVxacvkyBbdu4073wTc34BBDStFO5jByg2A2mU2IZpPZbDIX_MWhqbVf7HgL_9H17uG0Jz_OY0i3TIjlSzSADXBE_gu8nqvX</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>LOPES, JULIANA RAMOS</creator><creator>MASCHIO, LARISSA BAZELA</creator><creator>JARDIM-PERASSI, BRUNA VICTORASSO</creator><creator>MOSCHETTA, MARINA GOBBE</creator><creator>FERREIRA, LÍVIA CARVALHO</creator><creator>MARTINS, GUSTAVO RODRIGUES</creator><creator>GELALETI, GABRIELA BOTTARO</creator><creator>DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Evaluation of melatonin treatment in primary culture of canine mammary tumors</title><author>LOPES, JULIANA RAMOS ; MASCHIO, LARISSA BAZELA ; JARDIM-PERASSI, BRUNA VICTORASSO ; MOSCHETTA, MARINA GOBBE ; FERREIRA, LÍVIA CARVALHO ; MARTINS, GUSTAVO RODRIGUES ; GELALETI, GABRIELA BOTTARO ; DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-a7902f2a1987a425c8bb4336a01d02506ebb2709a301775d60adf06b1d8a60ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Breast cancer</topic><topic>Cell growth</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Dog Diseases - drug therapy</topic><topic>Dog Diseases - metabolism</topic><topic>Dogs</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Drug therapy</topic><topic>Estrogen</topic><topic>estrogen receptor</topic><topic>Estrogens</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>immunocytochemistry</topic><topic>Lymphatic system</topic><topic>Mammary Neoplasms, Animal - drug therapy</topic><topic>Mammary Neoplasms, Animal - metabolism</topic><topic>Medical prognosis</topic><topic>Melatonin</topic><topic>Melatonin - pharmacology</topic><topic>Metastasis</topic><topic>MT1</topic><topic>MT2</topic><topic>Physiological aspects</topic><topic>Primary Cell Culture</topic><topic>Receptor, Melatonin, MT1 - genetics</topic><topic>Receptor, Melatonin, MT1 - metabolism</topic><topic>Receptor, Melatonin, MT2 - genetics</topic><topic>Receptor, Melatonin, MT2 - metabolism</topic><topic>Rodents</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LOPES, JULIANA RAMOS</creatorcontrib><creatorcontrib>MASCHIO, LARISSA BAZELA</creatorcontrib><creatorcontrib>JARDIM-PERASSI, BRUNA VICTORASSO</creatorcontrib><creatorcontrib>MOSCHETTA, MARINA GOBBE</creatorcontrib><creatorcontrib>FERREIRA, LÍVIA CARVALHO</creatorcontrib><creatorcontrib>MARTINS, GUSTAVO RODRIGUES</creatorcontrib><creatorcontrib>GELALETI, GABRIELA BOTTARO</creatorcontrib><creatorcontrib>DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LOPES, JULIANA RAMOS</au><au>MASCHIO, LARISSA BAZELA</au><au>JARDIM-PERASSI, BRUNA VICTORASSO</au><au>MOSCHETTA, MARINA GOBBE</au><au>FERREIRA, LÍVIA CARVALHO</au><au>MARTINS, GUSTAVO RODRIGUES</au><au>GELALETI, GABRIELA BOTTARO</au><au>DE CAMPOS ZUCCARI, DEBORA APARECIDA PIRES</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of melatonin treatment in primary culture of canine mammary tumors</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2015-01</date><risdate>2015</risdate><volume>33</volume><issue>1</issue><spage>311</spage><epage>319</epage><pages>311-319</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Mammary neoplasias are the most common tumors observed in female dogs. Identification of these tumors is valuable in order to identify beneficial therapeutic agents as alternative treatments for this tumor type. Oral administration of melatonin appears to exert an oncostatic effect on mammary neoplasia and may have a possible mechanism of action through its interaction with estrogen receptors on epithelial cells. Hence, we analyzed the potential therapeutic value of melatonin in tumors that are estrogen-dependent or -independent, and established a relationship of its action with the expression of the melatonin receptors MT1 and MT2. Furthermore, we analyzed the rate of cell proliferation and apoptosis after treatment with melatonin. Cell cultures were performed using 10 canine mammary tumor fragments and were divided into estrogen receptor (ER)-positive and ER-negative tumors. The results showed that both ER-positive and ER-negative tumors had decreased cell viability and proliferation after treatment with melatonin (p<0.05), although treatment was more effective in the ER-positive tumors. Analysis of the relative expression of the MT1 and MT2 genes by quantitative PCR was performed and the data were compared with the expression of ER in 24 canine mammary tumors and the cellular response to melatonin in 10 samples. MT1 was overexpressed in ER-positive tumors (p<0.05), whereas MT2 was not expressed. Furthermore, melatonin treatment in ER-positive tumors showed an efficient oncostatic effect by inhibiting cell viability and proliferation and inducing apoptosis. These results suggest that melatonin decreased neoplastic mammary cell proliferation and viability and induced apoptosis, with greater efficacy in ER-positive tumors that have a high expression of melatonin receptor MT1. This is a strong evidence for the use of melatonin as a therapeutic agent for estrogen-dependent canine mammary tumors.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>25384569</pmid><doi>10.3892/or.2014.3596</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2015-01, Vol.33 (1), p.311-319 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1628241856 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Analysis Animals Antineoplastic Agents - pharmacology Apoptosis Breast cancer Cell growth Cell Proliferation - drug effects Cell Survival - drug effects Dog Diseases - drug therapy Dog Diseases - metabolism Dogs Drug Screening Assays, Antitumor Drug therapy Estrogen estrogen receptor Estrogens Female Gene Expression Genetic aspects Health aspects immunocytochemistry Lymphatic system Mammary Neoplasms, Animal - drug therapy Mammary Neoplasms, Animal - metabolism Medical prognosis Melatonin Melatonin - pharmacology Metastasis MT1 MT2 Physiological aspects Primary Cell Culture Receptor, Melatonin, MT1 - genetics Receptor, Melatonin, MT1 - metabolism Receptor, Melatonin, MT2 - genetics Receptor, Melatonin, MT2 - metabolism Rodents Tumor Cells, Cultured Tumors |
| title | Evaluation of melatonin treatment in primary culture of canine mammary tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A14%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20melatonin%20treatment%20in%20primary%20culture%20of%20canine%20mammary%20tumors&rft.jtitle=Oncology%20reports&rft.au=LOPES,%20JULIANA%20RAMOS&rft.date=2015-01&rft.volume=33&rft.issue=1&rft.spage=311&rft.epage=319&rft.pages=311-319&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2014.3596&rft_dat=%3Cgale_proqu%3EA401380414%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932658093&rft_id=info:pmid/25384569&rft_galeid=A401380414&rfr_iscdi=true |